Extramural Funding Opportunities |
|
Site map
Contact us |
Home | Funding | Advisory | NCI Initiatives | Funded Awards | Research Resources | Events | NCI News |
FOREWORD These Guidelines for the Program Project Grant of the National Cancer Institute are intended as a resource for prospective applicants and for reviewers of NCI program project (P01) applications. The Guidelines dated December 2003 are effective for all P01 applications submitted February 1, 2004 and later. Program Projects constitute one of the major extramural research mechanisms supported by the National Cancer Institute (NCI). The NCI has found the P01 grant mechanism to be particularly effective and highly productive, especially in areas where interdisciplinary collaboration and specialized core resources are needed to achieve a larger objective than can be supported through the traditional single project R01 grant. Submitting and reviewing a P01 application requires a substantial investment of effort by applicants, applicant organizations, NCI staff, and peer reviewers. To maximize the potential of this effort, prospective applicants are strongly encouraged to discuss their ideas with relevant NCI program staff prior to the submission of a formal application. Individuals should contact the NCI Referral Officer in the Division of Extramural Activities (DEA), NCI (E-mail: ncidearefof@dea.nci.nih.gov or 301-496-3428) for assistance in identifying appropriate NCI program areas and program staff. Applicants must obtain approval from the NCI at least six weeks prior to the anticipated submission of a P01 application (including amended applications and requests for supplemental funds) requesting $500,000 or more in direct costs in any one year (NIH Guide to Grants and Contracts, dated October 16, 2001 (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html). In addition, for Type 2 (competing continuation) applications budget requests for direct costs for the first requested year must not exceed an increase of 20 percent over the direct costs awarded in the last non-competing (Type 5) year. Details of the restrictions on budget requests are provided at this web site: http://deainfo.nci.nih.gov/flash/NCIPolicy_p01_escalation.htm. To determine the base for calculation of the maximal allowed increase in the first continuation year, the principal investigator is strongly advised to contact appropriate NCI program staff for assistance. It is a requirement that NCI P01 applications be prepared according to the instructions described in this document. The instructions for NCI application formatting refer to current procedures outlined in the Application for a Public Health Service Grant, PHS 398 (Rev. 5/01) as well as the latest changes in policies governing the submission, review and award of NCI P01s (see http://grants.nih.gov/grants/funding/phs398/phs398.html) (see http://grants.nih.gov/grants/funding). Applications not prepared using this or later versions of the PHS 398 application kit or not adhering to the instructions for preparation contained in this document may be returned without review. Applications involving clinical research must meet the NIH requirement for addressing the protection of human subjects from research risk; the inclusion of women, minorities and children in the study populations; and the plan for data and safety monitoring (for research involving clinical trials). Expected accruals must be presented in tabular form for each clinical study proposed. Applicants should refer to the information in this document and the PHS 398 instructions. Failure to provide such information will result in the application being returned as non-responsive, or deferral of review until adequate information is provided. Starting with the October 1, 2003 receipt date, investigators submitting an NIH application requesting research support of $500,000 or more in direct costs in any single year are expected to include a plan for data sharing or state why data sharing is not possible. This requirement is a reaffirmation of the NIH policy endorsing expedited translation of research results into knowledge, products and procedures to improve human health. Applicants should refer to the policy statements provided by the NIH Office of Extramural Research) (http://grants2.nih.gov/grants/policy/data_sharing/index.htm). The NIH continues to evolve policies governing all extramural awards, including program projects. Applicants are strongly encouraged, therefore, to make certain to obtain the latest policy and procedure information as the first step in preparing a new or renewal P01 application. Updated information and additional copies of the P01 Guidelines may be obtained over the Internet by accessing the Home Page of the National Cancer Institute Division of Extramural Activities at: http://deainfo.nci.nih.gov/awards/P01.htm. Further information and guidance may also be obtained from the NCI Referral Officer (see contact information below), or for current grantees, from your NCI Program Director.
Division of Extramural Activities National Cancer Institute 6116 Executive Blvd., Room 8041 Bethesda, MD 20892-8329 Rockville, MD 20852 (for courier delivery) 301-496-3428 301-402-0275 (FAX) ncirefof@dea.nci.nih.gov The process for submitting an NCI P01 application is different than that for most grant applications. All NCI P01 applications, including new, amended, supplemental and competing renewal applications, must be submitted on or before the P01 receipt dates February 1, June 1 or October 1. The original application and three copies are to be sent to the NIH Center for Scientific Review at the address provided in the PHS 398 form. Two copies of the application are to be sent directly to the NCI Referral Office at the above address. BEGINNING WITH APPLICATIONS SUBMITTED FOR THE FEBRUARY 1, 2004 RECEIPT DATE, NCI IS DOING A 1-YEAR PILOT STUDY OF REVIEWING P01 APPLICATIONS CLUSTERED IN GROUPS ACCORDING TO SIMILAR TOPIC AND/OR APPROACH. IN THIS PROCESS, TWO TO FOUR APPLICATIONS ON RELATED TOPICS WILL BE REVIEWED BY ONE REVIEW PANEL ENCOMPASSING APPROPRIATE EXPERTISE. APPLICATIONS WILL BE GROUPED BASED ON COMMONALITY OF SCIENTIFIC RESEARCH AREAS AND GENERAL TECHNICAL APPROACHES IN A MANNER SIMILAR THAT USED IN THE STUDY SECTIONS OF THE NIH CENTER FOR SCIENTIFIC REVIEW. SITE VISITS WILL NOT BE CONDUCTED AS PART OF THE REVIEW PROCESS.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SUMMARY OF CHANGES This page is a summary only. Detailed information is presented in the appropriate section. Changes in Review Process
Changes in Description of Application Preparation
REMINDERS
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PROGRAM PROJECT GRANT OF THE NATIONAL CANCER INSTITUTE I. INTRODUCTION The Program Project (P01) grant is a mechanism for the support of an integrated, multiproject research program involving a number of independent investigators who share knowledge and common resources. This type of grant has a well-defined central research focus involving several disciplines or several aspects of one discipline. The individual projects are interrelated and synergistic; hence, they result in a greater contribution to program goals than if each project were pursued separately. These Guidelines provide:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
II. DEFINITIONS AND IMPORTANT URLs FOR GRANTS POLICY
Accelerated Peer Review (APR) - A mechanism for accelerated re-review of P01 applications that are rated as highly meritorious, but fall outside the IC’s P01 payline. Awaiting Receipt of Application (ARA) - An internal NIH document submitted to CSR by NCI staff to indicate willingness to accept an application (a) requesting $500,000 or more in direct costs in any year, or (b) for programmatic relevance. Core - A separately budgeted component of the P01 that provides essential facilities or services to two or more of the proposed research projects. Draft Review Report - A preliminary compilation of reviewer critiques used by Scientific Review Groups to guide final discussion and assignment of overall priority scores to applications. Grants Management Specialist - The NCI official who serves as the focal point for all business-related activities associated with the negotiation, award and administration of grants. Letter of Intent - A non-binding notification submitted to NCI staff by a principal investigator indicating intent to submit an application. National Cancer Advisory Board (NCAB) - a Presidential-appointed chartered advisory committee to the Secretary, DHHS and the Director, NCI, composed of both scientists and lay members, which performs the final advisory review of grant applications and advises on matters of significance to the policies, missions and goals of the NCI. The members include outstanding authorities knowledgeable in relevant programmatic areas that are especially concerned with the health needs of the American people. National Cancer Institute Initial Review Group (NCI IRG) - a chartered advisory group composed primarily of non-Federal scientific experts who conduct the scientific and technical merit review (initial peer review) of grant applications and assign priority scores to meritorious applications. This large review committee is divided into a number of subcommittees or Scientific Review Groups (SRGs) which are analogous to study sections used throughout the NIH peer review system. P01 - The NIH activity code that identifies a Program Project application or grant. Principal Investigator - The one person designated by, and responsible to, the applicant/awardee institution for the scientific and administrative direction and proper conduct of all aspects of the P01. Program Director - the NCI scientist administrator responsible for the development of initiatives and for the scientific management of research programs sponsored by the NCI. This person serves as the focal point for all science related activities associated with the negotiation, award and administration of grants. Program Project Grant (P01) - an assistance award for the support of a broadly based multidisciplinary research program that has a well-defined central research focus or objective. It may also include support for common supporting resources (cores) required for the conduct of the component research projects. Interrelationships between projects are expected to result in a greater contribution to the program goals than if each project were pursued separately. Project - a research component of the P01 application with a separate detailed budget. Project Leader/Core Director - the investigator responsible for the scientific direction and conduct of an individual research project or core component of a P01. R01 - the NIH activity code that identifies an individual, investigator-initiated research project application or grant. Review Panel - an advisory group of scientific experts typically including representatives of an SRG subcommittee plus ad hoc members. These review panels perform the initial technical review of P01 applications and provide comments in the form of a Draft Review Report to the chartered SRG. Scientific Review Administrator (SRA) - the NCI scientist administrator responsible for the organization, management and documentation of the initial review process for applications. Scientific Review Groups (SRGs) subdivisions of the larger Initial Review Group, analogous to study sections used throughout the NIH peer review system. Currently, Subcommittees C (Basic and Preclinical), D (Clinical Studies) and E (Cancer Epidemiology, Prevention and Control) are responsible for review of P01 grant applications for NCI (see http://deainfo.nci.nih.gov/Advisory/irg/sub-cmte/index.htm). Special Emphasis Panel (SEP) - an advisory group of scientific experts drawn from a large pool of reviewers and chartered for the specific review or collection of reviews by a blanket chartering mechanism. The SEP is a second type of IRG. Summary Statement - the official record of the evaluation and recommendations of the IRG. Work Group - a review panel which reports to a parent committee. Work groups are commonly used to review multi-component applications such as P01s. The report from this review, a draft review report, is provided to the SRG where the final merit scoring is made. A work group may also be referred to as a review panel. Important URLs for Grants Policy
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
III. BACKGROUND
The P01 grant is intended solely for the support of multi-disciplinary or multifaceted research programs having a strong central theme. There are several features that distinguish P01 grants from other assistance mechanisms. Each project within a P01 is similar to the traditional research grant application in the sense that each is reviewed for scientific merit compared to a standard of quality in a broader scientific discipline. However, a component project also is evaluated within the context of the special collaborative interrelationships and environment required for a P01. Interaction between projects should be such that the acquisition of knowledge is accelerated or of a quality beyond that expected from the same projects conducted separately, without combined leadership or a common theme. Individual investigators apply their specialized research capabilities to basic research projects, clinical research projects, cancer control and cancer prevention research projects or combinations of such projects as they relate to the focused, central theme of the overall P01. Thus the P01 funding mechanism offers a special way to achieve research synergy through the sharing of personnel, facilities, equipment, data, ideas and concepts. A P01 should include a sufficient number of scientifically meritorious projects to promote an effective collaborative effort among the participating investigators. To be eligible for an award, a P01 must consist of a minimum of three scientifically meritorious projects. However, the P01 should not be so large that it exceeds the scientific and administrative leadership capability of the principal investigator, or that it loses a tight focus. Applicants should realize that the larger the program, the greater the likelihood that some components will be of lower quality. The inclusion of projects of lower quality or of peripheral relationship to the central theme will have a negative impact on the overall evaluation. The maximum number of research projects recommended, therefore, is six. Plans to submit applications with more than six projects should be discussed with the appropriate NCI Program Director. Alternatively, investigators considering research programs with a larger number of projects should consider submission of separate P01 applications each containing fewer projects. Please note that division of projects into subprojects in order to designate additional key investigators or to fragment the experimental approach is not permitted, nor are applicants permitted to incorporate projects or core components in the application for which no funds are requested. For Type 2/competing renewal applications, in particular, reference may be made to other non-P01 projects/activities to emphasize institutional resources and support. Finally, in P01 grants, neither are there allowances for unspecified developmental research funds (seed money) nor is there an allowance for developmental projects. A P01 grant application may contain one or more core component(s), each with a separate budget, for administrative or research support services that are required for and shared solely within a particular P01. Core components should be important to the overall success of the program, and each core must serve at least two projects. Core components may include research designed to improve core services. If a P01 application originates from an institution that is supported by an NCI Cancer Center Support Grant (P30), or there are Special Programs of Research Excellence (SPORE) (P50) on related research topics, a list of existing Cancer Center Shared Resources/Cores and SPORE resources and cores should be provided. If cores proposed within the P01 application duplicate existing institutional resources, clear justification should be provided for such duplication. Funds may be requested to supplement existing facilities in accordance with the needs of the P01. Central to the quality of a P01 is the leadership of the principal investigator and the other senior participating investigators. The principal investigator of the P01 should be an established scientist with a strong record of accomplishment who is substantially committed to, and exercises the responsibility for the scientific leadership, integration and administration of the entire P01. The principal investigator need not serve as a project leader or core director. The component projects should be directed by investigators who are experienced in the conduct of independent research as evidenced by grant awards and publications and whose backgrounds and interests relate sufficiently to one another to allow for integrated group pursuit of the proposed P01 goals and objectives. There is one designated project leader and one designated core director for each project and core. This named person is the one responsible for overall management and coordination of the component.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
IV. REVIEW CRITERIA
Peer review emphasizes a synthesis of two major aspects of the P01 application: (1) review of the merit of each of the individual research projects and core components compared to a standard of quality in its broad scientific discipline and (2) review of the program as an integrated research effort focused on a central theme. In arriving at an overall merit priority score for the P01, Scientific Review Group (SRG) members also will consider the likelihood that the proposed research program will have a substantial impact on the scientific field. The review criteria for both the overall program and the individual projects are the standard NIH review criteria of “Significance,” “Approach,” “Innovation,” “Investigators,” and “Environment” (NIH Guide, Vol. 26, Num. 22, June 27, 1997 [http://grants1.nih.gov/grants/guide/notice-files/not97-010.html]). The sections below give more detail about how these five criteria are applied to the overall program and the individual projects.
The leadership of the principal investigator is assessed according to the following criteria:
The integrated effort is assessed by considering the following criteria:
Projects may be “Not Recommended For Further Consideration" (NRFC) based on seriously flawed research approach or on inclusion of research hazardous to human subjects. Cores may be NRFC if they do not serve two or more projects or lack sufficient evidence of technical expertise and experienced leadership. (NOTE: Synergy and thematic relatedness between the projects and cores, and the significance of the project for the program as a whole, will be evaluated under “Program as an Integrated Effort" and/or in the “Overall Critique" sections.)
For P01s that involve human subjects, reviewers will examine (a) whether the applicant has adequately addressed the protection of human subjects, and (b) whether the involvement of minorities and children and the gender characteristics of the study population are scientifically acceptable and consistent with the aims of the project. Deficiencies in the application with respect to these issues will be considered in assessing merit of the research approach, and may impact on the recommended scientific merit rating of individual projects. If human subjects are involved, applicants should consult the instructions in the PHS 398 package as well as the on-line “NIH Policy and Guidelines on Inclusion of Women and Minorities as Subjects in Clinical Research.” (http://grants.nih.gov/grants/funding/phs398/section_1.html) and (http://grants.nih.gov/grants/funding/women_min/women_min.htm). For P01s that involve NIH-defined clinical research, investigators must report ethnic/racial enrollment in tabular form, as specified in the PHS 398 application. For those projects that involve clinical trials, investigators must include a general description of the Data and Safety Monitoring Plan in the application. (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-038.html)
Amended applications should be assessed based on the overall merit of the application including any progress made and the quality of changes made in response to the previous critique. An amended application may be improved, the same as, or worse than the previous application.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
V. ADVANCE COMMUNICATIONS WITH NCI STAFF
Research groups planning to submit a P01 application have found it useful to establish advance communications with relevant NCI staff. Such communications should begin at least three months prior to submission date. Specific issues that might be discussed include:
Applicants must obtain approval from the NCI at least 6 weeks prior to the anticipated submission of any P01 grant application, including requests for supplemental funds, requesting $500,000 or more in direct costs in any one year (NIH Guide to Grants and Contracts, dated October 16, 2001 [http:/grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html]. This rule also applies to amended applications and applications that have been delayed to a later submission date. An informative Letter of Intent, as described below, will assist NCI staff in preparing the ARA, the NIH internal document required for such approval, in a timely manner. Communications about intent to submit a P01 application should be with the NCI Referral Office. If the application is received without prior staff concurrence and identification of program staff contacted, it will be returned to the applicant without review. All applications including amended applications must have this permission six weeks in advance of the planned receipt date. If application submission is delayed, a new communication to the NCI Referral Office must be made to update NCI staff regarding the intent to submit the application. Although the Letter of Intent is not binding either for the planned submission date or for final detailed research content, the information provided also allows NCI review staff to estimate the potential review workload and to avoid conflict of interest in the review. The Letter of Intent should include at a minimum: The Letter of Intent should include as a minimum:
Letters of Intent should be sent to:
Division of Extramural Activities National Cancer Institute 6116 Executive Blvd., Room 8041 BETHESDA, MD 20892-8329 Rockville, MD 20852 (for courier delivery) 301-496-3428 301-402-0275 (FAX) ncirefof@dea.nci.nih.gov The Referral Office sends a copy to the Chief, Research Programs Review Branch and to the appropriate NCI program director. If you have previously been in communication with an NCI program director, please provide their name in the letter and forward them a copy of the letter.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
VI. SPECIAL INSTRUCTIONS for PREPARATION of PROGRAM PROJECT APPLICATIONS
General instructions for the preparation of the P01 grant application are contained in the Grant Application Form PHS 398 (Revised 05/01). Please note that the instructions provided in the PHS 398 document are designed primarily for traditional research project (R01) applications. P01 applications require additional information as outlined below. Clear and concise organization of the document is essential to the efficient study and review of the application. Page limitations are presented in the PHS 398 instructions; these should be followed closely for each individual project and core unless otherwise noted. Page limitations for the sections relating to the overall program are noted under the specific categories. When submitting the application, please attach a cover letter that includes the following information: the institute (NCI) which has agreed to accept the application (see NIH Policy), the name of the NCI program director, and response to a Program Announcement or RFA (if applicable),
Type "PROGRAM PROJECT" in the top left-hand corner of the face page immediately above the words "GRANT APPLICATION." Complete all items on the face page of the application as in a traditional research grant application. This is page 1 of the application; all succeeding pages should be numbered consecutively.
State concisely the overall goals of the entire P01 and clearly state the contribution of each component to the overall theme and goals. Under Performance Sites, list the applicant institution and all other sites where work described in the research plan will be conducted. Key personnel for the entire P01, including consultants and consortium collaborators, if any, should be listed alphabetically. To aid in the review of the application, include information concerning the distribution of effort of key personnel on each project and core. This could be presented in a tabular form such as that shown in Appendix B: Sample Table of Distribution of Professional Effort, NCI P01 Guidelines.
Prepare a detailed table of contents that enables reviewers to find specific information readily. Identify projects by number, title and responsible investigator. Identify cores by letter, title and responsible investigator. A sample Table of Contents is included at the end of these Guidelines as an example of how the order and format of the application could be organized (see Appendix A, NCI P01 Guidelines). For Type 2/competing renewal or amended/revised applications, in the event an existing project or core is discontinued or deleted, all projects and cores should be renumbered in sequence.
The PHS 398 Instructions (Sections 1-C4 and 1-C5) should be followed closely in preparing a detailed composite budget for all requested support for the first year using page 4 of the PHS 398 application. A summary budget for the entire proposed period of support should be prepared using page 5 of the PHS 398 application. The composite budgets should summarize all project/core expenses by category, i.e., personnel, equipment, and supplies. Budget requests for direct costs for Type 2/competing renewal P01 grant applications must not exceed an increase of 20 percent over the direct costs to be awarded in the last non-competing (Type 5) year. The Notice of Grant Award for the last grant period (Type 5) now includes an estimate of the budget cap allowed for the competing renewal application. The principal investigator is encouraged to contact NCI program staff for assistance in preparing budgets. (http://deainfo.nci.nih.gov/flash/NCIPolicy_p01_escalation.htm).
The narrative for the P01 should explicitly provide the required information in the order noted below. Efforts should be made to keep the narrative as concise as possible. Typically, eight to twelve pages are sufficient.
For P01s that involve human subjects, applicants must address (a) the protection of human subjects from research risk, (b) the inclusion of women, minorities and children in the study population, and (c) the plan for data and safety monitoring (for projects involving any type of clinical trials), in accordance with information provided in the "NIH Instructions to Reviewers For Evaluating Research Involving Human Subjects in Grant and Cooperative Agreement Applications" (http://grants.nih.gov/grants/peer/hs_review_inst.pdf). Deficiencies in the application with respect to these issues will be considered in evaluating the research approach, and may impact on the recommended scientific merit rating of individual projects. For P01s that involve NIH-defined clinical research, investigators must report ethnic/racial enrollment in TABULAR form, as specified in the PHS 398 application. For those projects that involve phase I and/or phase II clinical trials, investigators must include a general description of the Data and Safety Monitoring Plan in the application. If a phase III clinical trial is proposed, a Data and Safety Monitoring Board is required.
NIH policy requires the submission of Institutional Animal Care and Use Committee (IACUC) approval when animal studies are involved. The certification must be submitted with the application or within 60 days after the application receipt date. Otherwise, the application will be considered incomplete and deferred to the next review cycle.
Do not submit appendix materials with the application. The SRA for the review will give applicants a specific deadline for submitting the appropriate number of collated sets of appendix materials in the initial communication. The appendix material is to be sent directly to the SRA by the stated deadline. An exception is for P01s submitted in response to an RFA. In this instance, the appendix material should be submitted with the application. Appendix materials must be received in time to distribute to reviewers. Appendix materials submitted later than the date specified by the Scientific Review Administrator will be returned to the applicants. Appendix material can be submitted as electronic documents. However, all material should be submitted on one CD if possible. Details of electronic submission procedures will be provided by the SRA. Appendices should be clearly identified by project number and investigator, and may consist of the following materials:
The cores of a P01 may include laboratory and clinical facilities, equipment, and services that will be shared by two or more projects of the P01. A core may also include support for administration, such as the costs of fiscal and business management, consultant, secretarial and clinical services associated with the P01 unless these items are included in the institution's indirect cost rate.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
VII. SPECIAL INSTRUCTIONS for AMENDED/REVISED APPLICATIONS
Prepare an amended/revised application according to instructions provided in Section VI of these Guidelines. An amended application will be returned without review if substantive changes are not clearly apparent and identified.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
VIII. SPECIAL INSTRUCTIONS for COMPETING SUPPLEMENTAL APPLICATIONS
Requests for supplemental funds maybe submitted only for grants with at least two years of support remaining in the current award. A supplemental application is not accepted before the original application is awarded funding. The request for supplemental funds needs to have a well founded basis, such as unexpected costs and/or pursuance of an unanticipated scientific opportunity or continuation of a currently funded project/core. It should contain sufficient detail to permit an adequate evaluation of the requested expansion of the overall P01. A supplemental application will not be accepted if (a) it is to restore administrative cuts or (b) it does not fit within the scope of the existing P01 or extend the program=s scope in a clear and logical manner. If the request for supplemental funds exceeds $500,000, the NCI Referral Office must be notified by a letter of intent or direct communication with Referral Office staff. Consultation with the program director of the original application may precede the submission of a competing supplement application. All the information requested in these Guidelines (Section VI) should be included in the application, but adjusted to the requirements of the supplement as follows:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
IX. SPECIAL INSTRUCTIONS for PREPARATION of an ACCELERATED PEER REVIEW (APR) DOCUMENT
The National Cancer Institute (NCI) has established a procedure for the accelerated peer review (APR) of P01 applications. Applications that receive a highly favorable merit priority score but are not awarded funding may be eligible for an accelerated peer review. To be eligible for the APR process, the concerns noted in the summary statement must be addressable in a concise and straightforward manner. Examples would include deletion of a weak project or core, moderate changes in specific experiments or methods, addition of key preliminary data or expertise, or recent acquisition of an essential reagent. Inclusion of new projects or cores is not allowed. If a project is deleted, the amended P01 must still include a minimum of three research projects and the proposed cores must still serve two or more projects. Applicants will be notified by NCI program staff of their eligibility to submit an APR document in response to the previous review critique, in lieu of a fully amended application. The APR document will be considered by the P01 SRG or by a SEP prior to the next scheduled National Cancer Advisory Board meeting. This procedure, designed for applications requiring minimal amending, will normally save the time of one review cycle. The APR response submitted for consideration will count as one of the two amended application submissions currently allowed by the NIH. The NCI APR procedure, therefore, is available for new and competing renewal applications and applications that have been amended no more than one time. (Applications that have been amended twice are no longer eligible for additional reviews under current NIH rules.) (see the NIH Guide for Grants and Contracts [http://grants1.nih.gov/grants/guide/notice-files/not98-142.html]). NCI program staff will notify eligible principal investigators of the opportunity to submit an APR document in response to the summary statement critique (as described below) in lieu of an amended application. Specific dates for submission of a letter of intent and the receipt of the APR document for review will be clearly stated in the notification letter sent by NCI program staff. It is expected that this procedure will save time for applicants in the preparation of their responses and in the time involved in the peer review process. The APR review format will reduce the amended application review cycle from eight to approximately four months. However, all applicants eligible for APR will still have the option to decline the accelerated review process, to amend fully their application in the usual way, and resubmit in time for the next standard P01 application receipt date (February 1, June 1, or October 1).
Type “PROGRAM PROJECT APR” in the top left-hand corner of the face page immediately above the words “GRANT APPLICATION.” Complete all items on the face page as in a traditional research grant application. This is page 1 of the APR document; all succeeding pages should be numbered consecutively.
Page 2 from the previous application may be used, if it is still appropriate. If new key personnel are included as part of the application group, their names should be added to the Key Personnel section.
There is no specific format for the 20 page text. However, the document should have headings for each component of the application addressed in the APR response. It is anticipated that responses will be concentrated on those projects/cores or sections of the research plan needing the most revision. However, decisions about space allocation within the 20 page limit is vested with the applicant group.
Division of Extramural Activities National Cancer Institute 6116 Executive Blvd., Room 8041 BETHESDA, MD 20892-8329 Rockville, MD 20852 (for courier delivery) 301-496-3428 301-402-0275 (FAX) ncirefof@dea.nci.nih.gov
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
X. APPLICATION SUBMISSION PROCESS (for all applications except APRs)
Division of Extramural Activities National Cancer Institute 6116 Executive Blvd., Room 8041 BETHESDA, MD 20892-8329 Rockville, MD 20852 (for courier delivery) 301-496-3428 301-402-0275 (FAX) ncirefof@dea.nci.nih.gov It is to the advantage of the applicant to be certain that the Referral Office copies are submitted separately; this allows NCI staff to direct early attention to such issues as review scheduling and the need for additional information or materials required for peer review.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
XI. REVIEW PROCEDURES
The Scientific Review Administrator (SRA) serves as the Designated Federal Official (DFO) with legal responsibility for managing the review and ensuring that the review is conducted according to relevant laws, regulations, policy, and established NIH and NCI policies and procedures. The SRA provides guidance and direction with respect to review procedures and criteria; the need for a well-documented review; the functions of the NCI staff; conflicts of interest policies; implications of the Privacy Act; the need for confidentiality of the proceedings; the necessity of addressing gender, minority and children representation in clinical study populations; and other policy and logistic matters. The NCI program director serves as a resource, as needed, concerning the history and development of the program, changes in program direction and other relevant program matters.
Program project applications, like all other PHS grant applications, are received and initially processed by the NIH Center for Scientific Review (CSR). Following the current National Cancer Institute referral guidelines, the application is assigned to NCI and subsequently to a program area and to an SRA who manages the review. Applications that do not meet the referral guidelines for NCI programs are referred to another NIH institute.
Upon receipt, the SRA reviews the application for conformance to NIH policies and NCI Guidelines and discusses concerns with NCI program staff. If the deficiencies can be resolved easily post-submission, then the principal investigator is notified and remedial action is taken. If the deficiencies are extensive or cannot be resolved quickly, the application will be returned to the applicant without further consideration.
Beginning with applications submitted for the February 1, 2004 receipt date, NCI is undertaking a 1-year pilot study of reviewing P01 applications clustered according to similar topic and/or approach. In this new review process, SITE VISITS WILL NOT BE CONDUCTED. Thus, the success or failure of an application will depend first and foremost on how well the application text conveys the intent, merit and impact of the proposed research. Applications must be complete as submitted so that they can be reviewed without communication between the applicant and review groups. However, applicants will have an opportunity to respond to questions from the review panel, generally via teleconferencing. One review panel will review two to four applications on related topics. Applications will be grouped based on commonality of scientific research areas and general technical approaches in a manner similar to that used in the study sections of the NIH Center for Scientific Review. New, competing renewal and amended applications will, therefore, be reviewed together. Clusters may contain applications addressing a continuum of basic, translation or clinical related projects on closely related topics. Applications will be assessed according to a standard of P01 quality as defined in the P01 review criteria. The review panel will include senior investigators who can view the proposed science in a global perspective, specialists for specific scientific areas, and members of the three NCI P01 parent review committees for guidance in P01 review standards. Key members of the previous review panel will be included for continuity of review of the amended applications. In organizing the review panel membership, conflicts of interest, either real or perceived, will be avoided. Generally, applications submitted for review will be assigned to one of the three P01 SRGs: SRG-C (Basic Sciences), SRG-D (Clinical and Translational Studies) or SRG-E (Cancer Epidemiology, Prevention and Control). For those applications assigned to a SRG, a review of technical merit by a SRG work group/review panel typically precedes the final review and assignment of merit priority score by the SRG. An application will be reviewed by a Special Emphasis Panel (SEP) if a member of the applicant group is a current or recent member of the appropriate SRG. In the latter case, both technical merit evaluation and assignment of an overall program merit priority score will be the responsibility of the SEP. The review panel meeting date will be determined by the SRA according to the availability of suitable chairpersons and senior investigators. The applicants will be informed of the review date in advance. When possible, applicant schedules will be considered particularly with respect to the time zone. Applicant groups will be contacted by teleconference during the application review so that specific questions that impact program merit can be answered. Applicants may be given an opportunity to respond to key questions in writing prior to the review meeting. New data may be submitted with appendix material prior to the mailing of review materials to the panel members. The review panel will convene in a face-to-face meeting in the Washington, D.C. metropolitan area or elsewhere at the convenience of the reviewers. The agenda for the meeting will include an introductory orientation and planning session conducted by the SRA to discuss administrative and logistic matters relating to the review. Then, for each application, a preliminary discussion will be held to identify key information that needs to be obtained from the applicant group during a brief telephone conference. The telephone conference will be restricted to reviewer questions only. Formal presentations by applicants will not be permitted during the telephone conference. Major changes in projects, cores or aims will not be allowed either during the course of the telephone conference or before the final scoring of the application at the SRG meeting. After the telephone conference, the final discussion and technical assessment of the research plan and overall program will be completed. For those reviews conducted as an NCI SRG activity (work group/review panel), the reviewers' comments will be assembled as a Draft Review Report (DRR) that includes summaries of discussions of project/core merit, human subjects, and other review issues. These reports are forwarded to the NCI SRG for use in final discussion and assignment of overall merit priority score. Discussions of the NCI SRG are summarized and added to the DRR to form the final summary statement. If the review is conducted as a SEP, the reviewers' comments directly constitute the summary statement.
The SRA will contact the principal investigator concerning background information relevant to the application, names of investigators in collaboration with the members of the applicant group, other investigators who may be in conflict with the group, and the number of collated copies of appendix materials required for the review. The SRA will provide a deadline for receipt of appendix materials and any supplemental data obtained after submission of the application. This deadline, generally, will be five to six weeks prior to the review so that all materials related to the application(s) can be mailed to the reviewers in a timely manner. Major changes in scope or documentation that cannot be readily assimilated in the review process may result in deferral of review.
Shortly after receipt of the application, the SRA contacts appropriate NCI program staff and other individuals for supplemental information and recommendations for prospective reviewers where appropriate. Program and/or grants management staff members discuss with the SRA any unusual features of the application which might require additional material for reviewers, or any special problems that they anticipate in the review of the application. All review related communications with actual or potential reviewers are through the SRA.
The size and composition of each SRG work group (or SEP review panel) will be determined by the particular details of the applications to be reviewed. It is the responsibility of the SRA to make these determinations based upon thorough review of the applications and consultation with program and review staff. In identifying prospective qualified reviewers, the SRA takes full advantage of many available resources, including existing databases of experienced reviewers, lists of grantees and contractors, and consultation with recognized authorities in the scientific community. The SRA, as well as program staff, will identify reviewers who, because of collaboration, affiliation, or bias, should be excluded from the review. Applicants are prohibited from suggesting names of prospective reviewers. However, applicants may suggest expertise areas appropriate for inclusion in the review panel. Amended applications will have a core of membership from the previous review but there also will be new reviewers assigned to the application. The chairperson of the review panel, usually a SRG member, will be a senior investigator experienced in the review of complex multidisciplinary applications and generally knowledgeable in the broad scientific areas to be reviewed. The review panel membership will reflect a balance in terms of experience, expertise, and specialty so as to afford peer review of the separate components as well as the overall P01s in the cluster. A consultant experienced in management and fiscal administration may be needed when large P01s are reviewed. In most cases, this consultant does not vote on the scientific merit of the components or assign a priority score for the application, but does express opinion of the overall program administration. For relevant applications including clinical trials or population studies, a patient advocate/consumer will be included in the review group. These individuals, who have full scoring privileges, will speak to the importance of the research to the patient community and comment on human subject issues. The SRA may contact the principal investigator to discuss the specific disciplines or specialty areas of expertise that the principal investigator feels are required to review the application properly. However, as noted above, names of potential reviewers are not to be directly or indirectly solicited from the principal investigator by either the SRA or the program director assigned to the application. A limited number of individuals who, in the opinion of the principal investigator, may not be able to give an unbiased review may be submitted to the SRA. Full consideration is given to valid reasons presented by the principal investigator requesting that a particular reviewer not be invited, but the final decision rests with the SRA responsible for the review. The principal investigator should discuss these issues fully with co investigators before communicating this information to the SRA. When the arrangements for the review are completed, the SRA will advise the principal investigator and the program director in writing of the details, including the roster of the SEP or SRG review panel.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
XII. SUMMARY STATEMENT
The findings and recommendations of the reviewers are summarized in a written report which accurately conveys the evaluation of the P01. This summary statement is transmitted to the NCAB for advisory review, to the NCI official file and to the appropriate NCI staff. NCI program staff will automatically send a copy to the principal investigator as soon as the final document is available. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
XIII. AWARD
Following review by the NCAB, scored applications are considered for funding by NCI program staff and the NCI Executive Committee. When an award is made, it is the policy of NCI that meritorious projects reviewed as part of the P01 be funded as part of the P01 even though other funding may be available. Under no circumstances is duplicate funding awarded. NCI program staff may administratively delete funding or reduce the duration of support for components of P01s that are judged by peer review to be less meritorious and/or non essential to the conduct of the P01. The award and administration of P01s are subject to the same policies and procedures as other research grants. These policies and cost principles are set forth in the current PHS Grants Policy Statement, other NIH and NCI issuances and Federal legislation and regulations. Questions related to NCI P01 review may be directed to:
Deputy Branch Chief Research Programs Review Branch Division of Extramural Activities National Cancer Institute 6116 Executive Boulevard, Room 8125, MSC 8328 Bethesda, MD 20892-8328 Rockville, MD 20852 (Express Mail) Telephone: (301) 496-9236 FAX: (301) 496-6497 E-mail: vw8z@nih.gov
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
APPENDIX A: SAMPLE TABLE OF CONTENTS
SECTION I
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
APPENDIX B: SAMPLE TABLE OF PROFESSIONAL EFFORT
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
APPENDIX C: SAMPLE TABLE OF DISTRIBUTION OF CORE RESOURCES
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
top | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
National Cancer Institute (NCI) | National Institutes of Health (NIH) | Department of Health & Human Services (DHHS) | Links |